VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Wuliangye Yibin Co., Ltd. vs Novartis AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Wuliangye Yibin Co., Ltd.
000858 · Shenzhen Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Wuliangye Yibin Co., Ltd.'s moat claims, evidence, and risks.
View 000858 analysisNovartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisComparison highlights
- Moat score gap: Wuliangye Yibin Co., Ltd. leads (80 / 100 vs 65 / 100 for Novartis AG).
- Segment focus: Wuliangye Yibin Co., Ltd. has 3 segments (76.1% in Wuliangye-branded Baijiu products); Novartis AG has 5 segments (29.3% in Oncology).
- Moat breadth: Wuliangye Yibin Co., Ltd. has 5 moat types across 3 domains; Novartis AG has 4 across 3.
Primary market context
Wuliangye Yibin Co., Ltd.
Wuliangye-branded Baijiu products
China baijiu market (sales revenue; producers above designated size)
China
Consumers (premium gifting/banqueting; affluent households)
Branded spirits producer and marketer
76.1%
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Side-by-side metrics
Moat coverage
Shared moat types
Wuliangye Yibin Co., Ltd. strengths
Novartis AG strengths
Segment mix
Wuliangye Yibin Co., Ltd. segments
Full profile >Wuliangye-branded Baijiu products
Oligopoly
Other liquor products (Wuliang NongXiang and other series)
Competitive
Non-liquor products (other)
Competitive
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.